The Crossover I vehicle has been backed by CNP Assurances and an unnamed Chinese biopharmaceutical firm, and will target both late-stage private and public companies.

Samsung-backed nLight Photonics has filed for an initial public offering, aiming to raise approximately $86.3m when it floats on the Nasdaq Global Market.

Aptus Therapeutics-backed Alzheon has set its pricing range at $13 to $15 and could raise almost $86.3m if underwriters take up their option to purchase additional shares.

Unum Therapeutics has listed on the Nasdaq Global Select Market, providing exits to Novo, Sanofi, EMS and Seattle Genetics.

KU Leuven returned for the automated DNA diagnostic spinout's series A round, which follows a $2.3m round in 2016 and $1.5m raised in 2015.

Novartis-backed Homology Medicines priced its shares at $16 and raised $165m when it floated on the Nasdaq Global Select Market.

Following reports in February, Alibaba has confirmed it will acquire the remaining shares in Ele.me, currently owned by investors such as JD.com, Tencent and Baidu.